BridgeBio Pharma ($BBIO) Stock Hub 2026: The Attruby Ramp, A Negative Equity Balance Sheet And Two PDUFA Dates

01 Executive summary

BridgeBio Pharma is a commercial-stage company built around one approved medicine that is selling well and a balance sheet that looks nothing like a company selling well. Acoramidis, marketed as Attruby in the United States and as BEYONTTRA elsewhere, is an oral transthyretin stabiliser for transthyretin amyloid cardiomyopathy. In the second quarter of 2026 it produced $222.4 million of U.S. net product revenue, part of $243.7 million of total revenue, against $2.9 million in the partial launch quarter of late 2024. Seven consecutive quarters of sequential growth is an unusual record for a first launch in a competitive cardiology market.

The same quarter carried $149.4 million of research and development spending and $186.3 million of selling, general and administrative expense, which produced a $107.1 million operating loss and a $155.9 million net loss. Cash and equivalents stood at $677.9 million at June 30, 2026, or $720.2 million including marketable securities, down from $879.9 million three months earlier. The day after the quarter closed, the company took in $933.9 million of gross proceeds by issuing convertible preferred stock to Sixth Street and HealthCare Royalty at a 7.00% cumulative dividend.

Shareholders’ equity was negative $2.52 billion at the end of June. The arithmetic is straightforward: total liabilities of $3.72 billion, of which $2.51 billion of face-value convertible notes across four series and $879.4 million of deferred royalty obligations, against current assets of $1.09 billion. BridgeBio has funded a decade of drug development by selling claims on future revenue and by issuing convertible debt, and both choices show up as liabilities rather than equity.

Two regulatory decisions define the next eighteen months. BBP-418 in limb-girdle muscular dystrophy type 2I/R9 carries a Prescription Drug User Fee Act target action date of November 27, 2026, under priority review and with no advisory committee scheduled. Encaleret in autosomal dominant hypocalcemia type 1 carries a target action date of May 8, 2027, also under priority review and with no advisory committee. A third programme, oral infigratinib in achondroplasia, has an application filed with the U.S. Food and Drug Administration without a public action date, a European submission planned for the fourth quarter of 2026, and a U.S. launch the company places around the middle of 2027.

The immediate item is smaller and informational. On August 24, 2026 the company said five acoramidis presentations, two oral and three moderated ePosters, are scheduled for the European Society of Cardiology Congress in Munich between August 28 and 31, with three additional ePosters from an artificial-intelligence screening collaboration with Yale. Congress data on an approved medicine does not change the label, but it is what a cardiology sales organisation carries into the autumn prescribing season.

02 What the company is today, and the two entities that share the name

BridgeBio describes its structure as hub-and-spoke: autonomous teams work on individual genetic conditions, while a central function supplies clinical, regulatory and commercial capability. The model was designed for a portfolio of small patient populations where each programme on its own would struggle to justify a full company.

Two separately listed companies now carry the BridgeBio name, and confusing them is easy. BridgeBio Pharma, Inc. trades as $BBIO under Central Index Key 0001743881 and owns acoramidis. BridgeBio Oncology Therapeutics, Inc. trades as $BBOT under Central Index Key 0001869105 and is a distinct issuer running KRAS-directed oncology programmes. The oncology business was deconsolidated on April 30, 2024 after an outside financing round, completed a business combination with Helix Acquisition Corp. II on August 11, 2025 and began trading on the Nasdaq Global Market the following day. BridgeBio Pharma held 18.2% of it at June 30, 2026 and accounts for the holding under the equity method.

Beyond acoramidis, the commercial portfolio includes NULIBRY, or fosdenopterin, for molybdenum cofactor deficiency type A. It is a very small product against the acoramidis line and does not change the revenue picture.

03 The Attruby ramp, quarter by quarter

The launch curve is the strongest fact in the file, and it is worth reading as a sequence rather than as a single number.

Growth has decelerated in percentage terms while continuing in absolute terms, which is what a maturing launch looks like. The sequential increase was $34.6 million from the first to the second quarter of 2026, against $34.6 million from the fourth quarter of 2025 to the first of 2026 and $37.9 million in the quarter before that. Three consecutive quarters of roughly $35 million in added quarterly revenue is a steady addition of patients rather than an inflection, and it is the pattern that matters more than any single quarterly headline.

The competitive context is not in the filings but frames every one of those numbers: acoramidis entered a market where an established transthyretin stabiliser already held most of the treated population, and where a gene-silencing approach has since been approved for the same cardiomyopathy. The company positions acoramidis on the strength of near-complete stabilisation, defined as at least 90%, of the transthyretin tetramer, and every label outside the United States specifies that near-complete stabilisation.

04 Bayer, Alexion and the economics outside the United States

BridgeBio does not sell acoramidis outside the United States. Two licence agreements cover the major territories, and both were signed before the product was approved anywhere.

Bayer Consumer Care AG holds exclusive rights in the European Union and the states of the European Patent Organisation under an agreement effective March 1, 2024. The total value of upfront and milestone payments is up to $450.0 million, of which $210.0 million had been received by the June quarter, and royalties run on a tiered scale starting in the low thirties as a percentage of Bayer’s net sales. Alexion Pharma International Operations Limited holds exclusive rights in Japan, for a $25.0 million upfront payment and a $30.0 million regulatory milestone that was earned in full in May 2025 when national insurance pricing was set, with royalties in the low teens as a percentage of net sales.

The reported effect of those agreements moves in a way that can mislead. Licence and royalty revenue from the Japanese agreement was $3.1 million of royalty and $1.8 million of licence revenue in the first half of 2026, against $32.0 million and $31.0 million in the same period of 2025. The 2025 figures were milestone recognition, not recurring economics; the 2026 figures are the ongoing royalty stream. Bayer represented 30.1% of consolidated gross revenue in the first half of 2025 and fell below 10% in the first half of 2026, for the same reason: the U.S. product line grew and the milestone payments did not repeat.

The consequence for anyone reading the revenue line is that the growth is almost entirely U.S. product revenue, and that European and Japanese sales reach the income statement as royalty at a fraction of the gross, rather than as product revenue.

05 What the ESC 2026 programme actually contains

The August 24 announcement lists five company presentations and three from the Yale collaboration, at the European Society of Cardiology Congress in Munich from August 28 to 31, 2026.

Three further moderated ePosters come from the collaboration with Yale’s Cardiovascular Data Science Lab and concern earlier detection rather than the medicine itself: an artificial-intelligence electrocardiogram biomarker used inside a phase 3 randomised trial, a decentralised patient-led registry combining electronic health record and wearable data, and a multicentre analysis from a federated national screening network.

What this is, and what it is not, deserves precision. None of these are new randomised outcome trials. They are analyses of an existing pivotal study and its open-label extension, plus quality-of-life instruments and imaging endpoints. For an approved product competing on differentiation rather than on novelty, that is the intended use of a congress slot. The detection work with Yale addresses a different constraint entirely, which is that transthyretin amyloid cardiomyopathy is widely believed to be underdiagnosed, so the size of the treated population depends on screening as much as on prescribing.

August 26, 2026: the regression thesis gets a trial of its own

The imaging data going to Munich is not only being presented. On August 26, 2026 BridgeBio announced that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study built to test, prospectively and at greater depth, the question the CMR substudy raised: whether long-term acoramidis treatment improves cardiac structure and function rather than merely slowing their decline.

The design, as disclosed. ASCEND-ATTR is single-arm, prospective, longitudinal and open-label, and will enrol approximately 150 participants with ATTR-CM. Cardiovascular magnetic resonance and cardiac echocardiography are performed annually over 36 months. The primary efficacy endpoint is responder status at Month 36 by CMR, based on improvement from baseline in left ventricular systolic function. Secondary endpoints cover CMR measures of cardiac function, structure and amyloid burden at Month 36, plus echocardiographic measures, circulating biomarkers and imaging assessments at Months 12 and 24. The registration is NCT07695701.

What it builds on. The previously presented CMR substudy of ATTRibute-CM reported improvement from baseline through month 30 in left ventricular mass index, left ventricular stroke volume index and left ventricular ejection fraction, with evidence of amyloid regression in a subset of patients. The company’s mechanistic reading is that TTR stabilisation may allow innate amyloid clearance to exceed the rate of amyloid formation, enabling cardiac remodelling and functional recovery. Ahmad Masri of Oregon Health and Science University, quoted in the release, describes ASCEND-ATTR as the prospective study of those structural and functional changes, in a notably larger cohort and with two complementary imaging modalities.

What it is not. A single-arm open-label study with a responder endpoint at Month 36 is a characterisation study, not a controlled comparison, and the first readout on the primary endpoint sits three years out. The company itself frames the regression finding as a possibility raised by prior analyses rather than an established effect, and its own forward-looking language flags that observed improvements may not be replicated or translate into improved long-term clinical outcomes. For the equity, the near-term consequence is the ESC dataset above, not this trial. (Source: BridgeBio press release, August 26, 2026)

06 The pipeline behind acoramidis

Three programmes are close enough to a decision to matter to the next eighteen months.

The BBP-418 phase 3 trial, FORTIFY, met its primary and secondary endpoints at the twelve-month analysis according to the second-quarter release. Infigratinib carries breakthrough therapy, fast track and rare pediatric disease designations from the U.S. regulator and orphan designation on both sides of the Atlantic. The depleter programme is the company’s attempt to hold the transthyretin franchise beyond stabilisation, and it is years away from a commercial decision.

Two of these three near-term filings target populations measured in thousands rather than tens of thousands. That is the arithmetic the hub-and-spoke structure exists to handle, and it is also why a rare pediatric disease designation, which can produce a priority review voucher on approval, is a line item rather than a footnote.

07 Financial position at June 30, 2026

The two net loss lines are different numbers and the difference is not rounding. The total loss includes amounts attributable to non-controlling interests; the attributable line is what divides into the share count to produce earnings per share. The first-half figures show the same relationship at a larger scale.

The distance between the operating loss and the net loss is the cost of the capital structure. In the second quarter the operating loss was $107.1 million and the net loss $155.9 million, a gap of $48.8 million driven by financing charges rather than by operations. That gap is the recurring price of the notes and the royalty obligations described in the next section, and it does not shrink as revenue grows unless the instruments themselves change.

Cash and stated runway

Cash and equivalents were $677.9 million at June 30, 2026, against $879.9 million at March 31 and $570.1 million at December 31, 2025. Including marketable securities the company reported $720.2 million. Current assets totalled $1.09 billion. The quarterly sequence is not a straight line because financings land in single quarters, and the December-to-March increase reflects one of them.

The statement of liquidity in the Form 10-Q filed August 10, 2026 says the company expects cash, equivalents, marketable securities and proceeds from Attruby product revenue to be sufficient to fund operations through at least the next twelve months from the filing date. That language is the standard formulation and it is deliberately bounded at twelve months. No break-even date or profitability target appears in the documents reviewed.

08 Why shareholders’ equity is negative $2.5 billion

A company with $243.7 million of quarterly revenue and $15.85 billion of market capitalisation reporting negative equity of $2.52 billion looks like a contradiction. It is not: it is the record of how the last decade of development was financed.

The convertible notes

All four series are senior unsecured. The 2027 and 2031 notes became convertible at the holder’s option for the window running from July 1 to September 30, 2026, because a share-price condition was triggered. A conversion settled in cash would draw on liquidity; a conversion settled in shares would add to the share count. The risk factors in the Form 10-Q name that window explicitly.

The royalty financings

Two separate transactions sold claims on future acoramidis revenue. Under a funding agreement dated January 17, 2024 with LSI Financing 1 DAC and CPPIB Credit Europe, $500.0 million net of expenses was paid to the company on the first U.S. approval of Attruby and received in December 2024; the net carrying value of that deferred royalty obligation was $570.1 million at June 30, 2026. In June 2025 a royalty purchase agreement with an entity affiliated with HealthCare Royalty and with a fund affiliated with Blue Owl Capital brought in $300.0 million of cash in exchange for 60% of European royalties on the first $500 million of annual BEYONTTRA net sales, subject to a cap initially set at 145% of the purchase price; the carrying value was $309.3 million. Together the deferred royalty obligations stood at $879.4 million, against $855.0 million at the end of 2025.

A term loan facility of $750 million arranged with Blue Owl Capital in January 2024 was repaid in full on February 28, 2025 out of the 2031 note proceeds, producing a $21.2 million loss on extinguishment in the first half of 2025. No balance remains.

How to read the negative number

Royalty monetisations bring cash in without issuing shares, and both the cash received and the obligation created sit on the liability side while the accumulated deficit sits in equity. The result is a balance sheet where the equity line carries almost no information about the value of the business, and where the questions that do matter are different ones: whether the royalty obligations are capped, what fraction of revenue they divert, when the notes mature, and whether the cash flow covers them. The 2027 maturity is the first hard date, in March 2027.

09 The preferred financing that closed on July 1, 2026

The day after the second quarter ended, BridgeBio closed an investment agreement with Chinotto Investments, an entity connected to Sixth Street, and with HCRx Investments HoldCo, connected to HealthCare Royalty. The company issued 933,900 shares of Series A Cumulative Convertible Participating Preferred Stock at $1,000 per share for gross proceeds of $933.9 million, of which $800.0 million from Sixth Street and $133.9 million from HealthCare Royalty.

Three features carry weight. The conversion price of $137.79 sat more than 100% above the thirty-day volume-weighted average price at signing, so the instrument does not convert on any near-term move in the shares. The dividend is cumulative and escalates, and the option to pay it in kind means the obligation can compound rather than consume cash. And the preferred ranks ahead of common stock on both dividends and liquidation, which changes the order of claims without appearing in the share count.

The practical effect on liquidity is large and is not visible in the June 30 balance sheet. Cash of $677.9 million at the quarter end plus $933.9 million of gross proceeds the following day is a materially different starting position for the November and May decisions than the quarter-end figure alone suggests.

10 The 18.2% stake in $BBOT

BridgeBio Oncology Therapeutics began life inside BridgeBio Pharma as TheRas, Inc. A $200.0 million private financing with outside investors led to deconsolidation on April 30, 2024, after which the holding has been accounted for under the equity method rather than line-by-line. The oncology company completed its combination with Helix Acquisition Corp. II on August 11, 2025 and started trading on Nasdaq as $BBOT the next day. At June 30, 2026 BridgeBio Pharma held 18.2%.

For a reader of the $BBIO accounts this matters in two ways. The oncology programmes, which are KRAS-directed, no longer consume research and development expense on this income statement, and their clinical results do not appear in these filings. The stake is an asset whose value moves with a separately quoted share price, and $BBOT closed at $9.14 on August 24, 2026 for a market capitalisation of about $732.8 million. Merlintrader covers the oncology company separately in the $BBOT stock hub.

11 Catalyst table

Regulatory target action dates are dates the agency works to, not guarantees, and they can be extended when a submission is classified as a major amendment. The company windows above are statements of intent made in the second-quarter release of August 10, 2026 and can move.

12 The two cases as their holders put them

What the constructive case rests on

Supporters point to a launch curve that has added roughly $35 million of quarterly revenue for three consecutive quarters without a stumble, in an indication where the diagnosed population is generally held to be a fraction of the true one. They point to labels outside the United States that specify near-complete stabilisation, which gives the commercial organisation a differentiating claim rather than a price argument. They note that two further approvals are scheduled inside eighteen months, both under priority review and neither carrying an advisory committee, and that a third filing is already with the agency. And they argue that the negative equity is an artefact of choosing royalty monetisation over dilution, which left the share count at 195.3 million rather than several times that.

What the sceptical case rests on

Sceptics start with the same balance sheet and read it differently: $2.51 billion of notes with the first $550.0 million maturing in March 2027, $879.4 million of royalty obligations that divert revenue before it reaches the income statement, and a new preferred layer that ranks ahead of common holders and pays a compounding dividend. They observe that the second-quarter operating loss was still $107.1 million on record revenue, that selling and administrative spending of $186.3 million exceeded research spending of $149.4 million, and that the gap between operating and net loss is a structural $48.8 million a quarter. They note the concentration risk stated in the company’s own filings: one product generates essentially all material revenue, and outside the United States the company depends on partners it does not control. And they point out that the November and May decisions are binary, and that neither has an advisory committee scheduled, which removes a public preview of the agency’s thinking.

13 Scenario framework, not a forecast

The scenarios below describe how the company’s own disclosed variables could combine. They carry no probabilities and no price levels.

14 Bottom line

BridgeBio Pharma is two things at once, and the tension between them is the story. It is a company whose first commercial launch has worked, taking acoramidis from $2.9 million to $222.4 million of quarterly U.S. revenue in seven quarters, with regulatory approvals across the United States, Europe, Japan, Switzerland, the United Kingdom and Brazil. It is also a company that financed that decade with $2.51 billion of convertible notes, $879.4 million of royalty obligations and, since July 1, $933.9 million of preferred stock that outranks its common shareholders, and that still lost $155.9 million in its best revenue quarter to date.

The ESC presentations on August 28 to 31 are the near-term item and the smallest of them. They add analyses of an existing pivotal trial and its extension to the commercial argument for an approved medicine. The dates that decide the shape of the company are November 27, 2026 and May 8, 2027, with March 15, 2027 sitting between them as the first note maturity.

Primary Sources And Reference Links

• BridgeBio announcement of the ESC Congress 2026 presentations, August 24, 2026 — presentation titles, presenters, formats and session times.
• Form 10-Q for the quarter ended June 30, 2026, filed August 10, 2026 — revenue, expenses, losses, cash, liabilities, equity, notes, royalty obligations, the BBOT stake and the subsequent-event disclosure of the preferred financing.
• Form 8-K of August 10, 2026 with the second-quarter results release — pipeline milestones, regulatory dates and stated company windows.
• Form 8-K of July 2, 2026 — closing of the Series A preferred investment agreement, size, dividend, conversion price and ranking.
• Form 8-K of July 22, 2026 — acceptance of the encaleret application and the May 8, 2027 target action date.
• SEC EDGAR — all BridgeBio Pharma, Inc. filings, CIK 0001743881
• SEC EDGAR — all BridgeBio Oncology Therapeutics, Inc. filings, CIK 0001869105
• Finviz price, market capitalisation and volume fields read August 24, 2026

Evidence note. Quarterly Attruby revenue figures are taken from the exhibit 99.1 results releases filed with each quarterly Form 8-K from February 2025 to August 2026. Balance-sheet and income-statement figures are from the Form 10-Q for the quarter ended June 30, 2026. Note face values are principal amounts and differ from carrying values. Market data is third-party and changes continuously. Licence terms with Bayer and with Alexion are as described in note 10 of that Form 10-Q.